EC approves subcutaneous Herceptin

The European Commission approved a subcutaneous formulation of Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat HER2-positive breast cancer. Roche said subcutaneous administration of Herceptin is less invasive and takes two to five minutes instead of 30-90 minutes with the IV administration. Roche's Genentech Inc. unit markets IV Herceptin in the U.S., while Roche markets it elsewhere. ...